During the recent session, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s traded shares were 1.56 million, with the beta value of the company hitting 1.07. At the last check today, the stock’s price was $13.45, reflecting an intraday gain of 1.51% or $0.2. The 52-week high for the TEVA share is $14.47, that puts it down -7.58 from that peak though still a striking 47.29% gain since the share price plummeted to a 52-week low of $7.09. The company’s market capitalization is $15.08B, and the average trade volume was 10.07 million shares over the past three months.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) trade information
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) registered a 1.51% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.51% in intraday trading to $13.45, hitting a weekly high. The stock’s 5-day price performance is 4.59%, and it has moved by -6.79% in 30 days. Based on these gigs, the overall price performance for the year is 63.82%.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) estimates and forecasts
Statistics show that Teva- Pharmaceutical Industries Ltd. ADR has underperformed its competitors in share price, compared to the industry in which it operates. Teva- Pharmaceutical Industries Ltd. ADR (TEVA) shares have gone up 63.82% during the last six months, with a year-to-date growth rate less than the industry average at -7.42% against 21.80. In the rating firms’ projections, revenue will increase 0.10% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 3.73B as predicted by 7 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 4B by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 26.63%. While earnings are projected to return -6.18% in 2024, the next five years will return 1.60% per annum.
TEVA Dividends
Teva- Pharmaceutical Industries Ltd. ADR is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
